IMAVITA S.A.S., an innovating technology company providing services in preclinical models of human pathologies released a poster related to efficacy of BoNT in Rhino mouse model of acne:
Poster summary available on Sciencedirect website page and pdf of abstract is available.
Poster was presented at Toxins 2022 congress, New-Orleans, USA.
Imavita is proud to announce new team members with the recent recruitment of Pierre-Yves Fortin and Pauline Auriol.
Pierre-Yves Fortin, PhD, Preclinical imaging, Project Leader, Pierre-Yves is a PhD graduated on 2011 and Post-Doc in 2020 with an important background and experience with preclinical models, preclinical imaging (fluorescence, bioluminescence, ultrasonography, elastography, etc…) in oncology.
Pauline Auriol, Apprentice Bachelor Degree (BSc), Research Scientist Assistant. Pauline is actually graduating Vocational Bachelor’s Degree in Analytical and Experimental Biology from University of Montpellier, France.
Pauline works now at Imavita with in vivo models for drug efficacy evaluation principally.
IMAVITA and all is team wish to all customers, suppliers, collaborators and families, a Happy New Year and Best Wishes for 2021!
In 2021, add scientific value to your preclinical research projects with IMAVITA!
Click on the image to see animation:
Some words on Imavita’s season’s greetings eCard:
Imavita is proud to announce a new team member with the recent recruitment of Claire Coustal.
Claire Coustal, Apprentice MSc, Research Scientist Assistant. Claire is actually graduating Master 2 (M2) Innovating Drug therapies and Biotherapeutics (“Biothérapies et Médicaments de Thérapie Innovante”) from University of Nantes, France.
Claire works now at Imavita in the in vitro lab and in vivo models for drug efficacy evaluation principally in the field of Osteo-Articular disease and Neurology/Neuro-Inflammation.
IMAVITA S.A.S., an innovating technology company providing services in preclinical models of human pathologies associated with imaging and image analysis, announces its participation in the collaborative project PICSTEM.
This 2-years project will focus on the fields of osteo-articular diseases (Psoriatic Arthritis, Osteo-Arthritis and Ankylosing Spondyloarthritis) and neurology (neuro-inflammation in Recurrent-Remittent Multiple Sclerosis and Sciatic nerve inflammation).
IMAVITA will actively participate in this project by providing technical and scientific expertise and relevant preclinical models of human pathologies.
This project will allow IMAVITA to develop new animal models and develop new translational services in preclinical and clinical imaging.
Partners participating in PISCTEM project:
Cell-Easy https://cell-easy.com
Imavita https://imavita.com
Stromalab https://www.stromalab.fr/en/
Ambiotis
Imavita and all is team wish to all customers, suppliers, collaborators and families, a Happy New Year and Best Wishes for 2020!
Accelerate your R&D projects in the next decade with preclinical models and preclinical imaging!
Some words on Imavita’s season’s greetings eCard:
Imavita is proud to announce New Team members with the recent recruitment of Maud Chusseau and Julia Rochotte.
Maud Chusseau, MSc, Research Scientist, Maud is graduated from University of Lyon, France (Master Pharmacology / Animal experimentation 2007). Maud has several industry experiences (SeleXel, Endotis Pharma, Galapagos, Servier). Maud works now at Imavita in the in vitro lab and in vivo models for drug efficacy evaluation and has experience in qPCR, animals surgery and small animal imaging.
Julia Rochotte, PhD, Immunologist, Project Leader, Julia is a young PhD graduated on 2014. She has spent 7 years at the laboratory of the Center of Oncology Research of Toulouse (Centre de Recherche en Cancérologie de Toulouse (CRCT) U1037 INSERM / UPS / CNRS) with an important background in immunology and immuno-oncology.
All the team of Imavita wishes to all collaborators, colleagues, customers and suppliers and their families, an excellent and happy new year 2019!
IMAVITA S.A.S., an innovating technology company providing services in preclinical models of human pathologies associated with imaging and image analysis, announces its participation in the collaborative project Pi-R2 / Innovative Technical Radiofluorination Platform for Radiochemistry and Radiopharmacy of Fluor-18.
This 3-year project will focus on the fields of oncology, cardiovascular and neurology, for which 4 work teams have been created:
IMAVITA will actively participate in this project by providing technical and scientific expertise and relevant preclinical models of cancer, atherosclerosis and Alzheimer’s disease.
This project will allow IMAVITA to develop new animal models, access custom and innovative radio tagging skills, explore existing preclinical models in PET/CT imaging and develop new translational services in preclinical and clinical imaging.
Partners participating in the Pi-R2 project:
ToNIC (Toulouse NeuroImaging Center) http://tonic.inserm.fr
LCC CNRS https://www.lcc-toulouse.fr/
CREFRE https://www.iuct-oncopole.fr/le-crefre
CRCT https://www.crct-inserm.fr/
I2MC http://www.i2mc.inserm.fr/
Zionexa http://zionexa.com
Imavita https://imavita.com
IMAVITA S.A.S., société de services et d’innovation dans les modèles précliniques de pathologies humaines associées à l’imagerie et l’analyse d’images, annonce sa participation au projet collaboratif PiR2 / Plateau Technique innovant de Radiochimie et de Radiopharmacie du Fluor-18.
Ce projet de 3 ans sera axé dans les domaines de l’oncologie, cardio-vasculaire et neurologie et pour lesquels 4 équipes de travail ont été créées :
1/ Synthèse, purification et analyse structurale de précurseurs de radio-marquage avec le Fluor 18 et mise au point des diverses synthèses de molécules radio-fluorées,
2/ Production des molécules radio-marquées pour injection dans des modèles pré-cliniques,
3/ Développement et mise en place des modèles animaux pathologiques, imagerie PET/CT et analyse quantitative des données d’imagerie pour validation du ciblage thérapeutique,
4/ Production en qualité pharmaceutique et utilisation des productions de produits radio-marqués dans le cadre d’essais cliniques
La société IMAVITA participera activement à ce projet par la mise à disposition de compétences techniques et scientifiques et la fourniture de modèles précliniques pertinents de cancer, d’athérosclérose et de maladie d’Alzheimer.
Ce projet permettra à IMAVITA le développement de nouveaux modèles animaux, l’accès à des compétences de radio-marquage à façon et innovants, l’exploration en imagerie PET/CT de modèles précliniques existants et de nouveaux services translationnels en imagerie préclinique et clinique.
Partenaires participant au projet PiR2:
ToNIC (Toulouse NeuroImaging Center) http://tonic.inserm.fr
LCC CNRS https://www.lcc-toulouse.fr/
CREFRE https://www.iuct-oncopole.fr/le-crefre
CRCT https://www.crct-inserm.fr/
I2MC http://www.i2mc.inserm.fr/
Zionexa http://zionexa.com
Imavita https://imavita.com